We narrowed to 69 results for: aav gfp cre

#51502-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

June 15, 2020

Academic Institutions and Nonprofits only

#124364-AAV2

Ready-to-use AAV2 particles produced from pAAV-FLEX-DTR-GFP (#124364). In addition to the viral particles, you will also receive purified pAAV-FLEX-DTR-GFP plasmid DNA. CBA-driven, Cre-dependent expression of DTR-GFP. These AAV preparations are suitable purity for injection into animals.

Eiman Azim, Thomas Jessell

Azim et al Nature. 2014 Apr 17;508(7496):357-63. do

June 16, 2020

Academic Institutions and Nonprofits only

#50457-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#84445-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-drive, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 12, 2017

Academic Institutions and Nonprofits only

#119741-AAV5

Ready-to-use AAV5 particles produced from AAV SYN flex PSAM4 GlyR IRES EGFP (#119741). In addition to the viral particles, you will also receive purified AAV SYN flex PSAM4 GlyR IRES EGFP plasmid DNA. Synapsin-driven, Cre-dependent expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

April 5, 2019

Academic Institutions and Nonprofits only

#51502-AAV5

Ready-to-use AAV5 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Oct. 3, 2019

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#112677-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

July 16, 2019

Academic Institutions and Nonprofits only

#100043-AAV9

Ready-to-use AAV9 particles produced from pAAV.synP.DIO.EGFP.WPRE.hGH (#100043). In addition to the viral particles, you will also receive purified pAAV.synP.DIO.EGFP.WPRE.hGH plasmid DNA. Synapsin-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

April 20, 2018

Academic Institutions and Nonprofits only

#100798-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-FLEX-splitTVA-EGFP-tTA (#100798). In addition to the viral particles, you will also receive purified pAAV-syn-FLEX-splitTVA-EGFP-tTA plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-TREtight-mTagBFP2-B19G (Addgene#100799). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#50457-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 17, 2020

Academic Institutions and Nonprofits only

#51502-AAV2

Ready-to-use AAV2 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 7, 2018

Academic Institutions and Nonprofits only

#107712-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin-FLEX-soCoChR-GFP (#107712). In addition to the viral particles, you will also receive purified pAAV-hSynapsin-FLEX-soCoChR-GFP plasmid DNA. Synapsin-driven, Cre-dependent somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#100799-AAV1

Ready-to-use AAV1 particles produced from pAAV-TREtight-mTagBFP2-B19G (#100799). In addition to the viral particles, you will also receive purified pAAV-TREtight-mTagBFP2-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-syn-FLEX-splitTVA-EGFP-tTA (Addgene# 100798). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#52473-AAV1

Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

Dec. 18, 2018

Academic Institutions and Nonprofits only

#119741-AAV9

Ready-to-use AAV9 particles produced from AAV SYN flex PSAM4 GlyR IRES EGFP (#119741). In addition to the viral particles, you will also receive purified AAV SYN flex PSAM4 GlyR IRES EGFP plasmid DNA. Synapsin-driven, Cre-dependent expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Jan. 26, 2021

Academic Institutions and Nonprofits only

#51502-AAV8

Ready-to-use AAV8 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Jan. 26, 2021

Academic Institutions and Nonprofits only

#108422-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-FLEX-Archon1-KGC-EGFP-ER2 (#108422). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-Archon1-KGC-EGFP-ER2 plasmid DNA. CAG-driven, Cre dependent Archon1, an opsin-based fluorescent voltage indicator, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Piatkevich et al Nat Chem Biol. 2018 Feb 26. pii: 10.1038

Sept. 17, 2018

Academic Institutions and Nonprofits only

#84445-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Aug. 24, 2020

Academic Institutions and Nonprofits only

#83895-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only